Teaching old drugs new tricks

Abstract

Pharmaceutical research is associated with high costs, both in terms of time and money. In the last year, drugs with a value of over $20 billion have come off patent, meaning many pharma giants face a crisis in their late-stage product pipeline. This, in addition to the high risks involved in getting a drug to market, encourages maximal exploitation of drugs already proven safe.